Table 3 Clinical studies of targeted agents for the treatment of SCLC

From: Treatment options for small cell lung cancer – do we have more choice?

      

Result

 

Authors

Targeted agent

Combination regimen

Targeted population

Phase

Sample size

RR

OS/PFS (months)

Conclusion

TKs inhibitors

 Dy et al (2005)

Imatinib

—

Relapsed, resistant/sensitive [c-Kit +]

II

29

No PR

No SD

OS: R=3.9

S=5.3

No clinical activity

 Krug et al (2005)

 

—

Relapsed, resistant/sensitive [c-Kit +]

II

12

No PR

No SD

OS: 2

No clinical activity

 Johnson et al (2003)

 

—

ES, untreated relapsed, sensitive

II

19

No PR

—

No clinical activity

 Schneider et al (2006)

 

—

ES, if no PD after I-line IP × 4 [c-Kit +]

II

14

No PR

OS: 10

Disease stability not maintained

 Spigel et al (2007)

 

Carboplatin/irinotecan

ES, untreated

II

69

PR 66%

OS: 8.4

No improvement in results from chemotherapy alone

 Moore et al (2006)

Gefitinib

—

Relapsed, resistant/sensitive

II

19

No PR 10% SD

OS: 206 days

No clinical activity

Anti-angiogenic agents

 Sandler et al (2007)

Bevacizumab

Cisplatin/etoposide

ES, untreated

II

64

OR 69%

PFS at 6 months: 33%

Promising results

 Ready et al (2007)

 

Irinotecan/cisplatin

ES, untreated

II

72

CR 3%

PR 71%

OS: 11.7

Primary end point not reached

 Jalal et al (2008)

 

Paclitaxel

Relapsed, sensitive

II

34

PR 11%

SD 55%

OS: 21 weeks

Active regimen

 Pujol et al (2007)

Thalidomide

PCDE

ES, after response to PCDE × 2

III

119

—

OS: 11.7/8.7 (NS)

Thalidomide did not improve survival

 Lee et al (2008)

 

Carboplatin/etoposide

ES and LS, untreated

III

724

—

OS: 10.2/10.5 (NS)

Thalidomide did not improve survival

 Gitlitz et al (2008)

Sorafenib

—

Relapsed (platinum-treated)

II

81

PR 4%

SD 32%

−7, S

−5, R

Clinical activity

 Ramalingam et al (2008)

Cediranib (ZD2171)

—

Relapsed (platinum-treated)

II

25

PR: 1 patient

SD: 9 patients

PFS 1.2

No clinical activity

 Arnold et al (2007)

Vandetanib (ZD6474)

—

ES and LS, untreated. If no PD after first-line platinum-based (and PCI/TRT)

II

107

—

PFS and OS NS

No efficacy as maintenance therapy

  1. Abbreviations: RR=response rate; PR=partial response; SD=stable disease; OS=overall survival; PD=progressive disease; ES=early-stage; PFS=progression-free survival; CR=complete response; PCDE=etoposide plus cisplatin and cyclophosphamide plus 4′-epidoxorubicin; LS=late stage; S=sensitive; R=resistant; NS=not significant; PCI=prophylactic cranial irradiation; TRT=thoracic radiotherapy; OR=overall response.
Back to article page